– Remedy Meds acquires Thirty Madison for $500M.
– Thirty Madison competes with Hims and Ro.
Remedy Meds acquisition of Thirty Madison for $500 million marks a significant expansion in the virtual healthcare sector. Remedy Meds, known for selling GLP-1 weight loss medications and providing telehealth services, aims to enhance its consumer reach through this acquisition. Thirty Madison, a virtual care startup, competes with companies like Hims and Ro, offering specialized healthcare services.
The acquisition involves a cash transaction valued at $500 million. Remedy Meds plans to integrate Thirty Madison’s platform to broaden its service offerings. This move is expected to increase Remedy Meds’ market share in the telehealth industry, which has seen rapid growth in recent years.
Thirty Madison’s platform focuses on chronic condition management, providing personalized treatment plans for conditions such as hair loss, migraines, and gastrointestinal issues. By acquiring Thirty Madison, Remedy Meds aims to diversify its portfolio and offer a wider range of healthcare solutions to its customers.
The deal is expected to close by the end of the year, subject to regulatory approvals. This acquisition aligns with Remedy Meds’ strategy to expand its digital health footprint and enhance its competitive position in the market. The integration of Thirty Madison’s services is anticipated to provide Remedy Meds with a competitive edge in the rapidly evolving telehealth landscape.
For more information on similar transactions, visit our Mergers & Acquisitions page. To learn more about regulatory processes, see the FDA website.